FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Farrell Geraldine T 		2. Issuer Name and Ticker or Trading Symbol

Nexvet Biopharma plc [ NVET ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
VP Operations & Genl Counsel
(Last)          (First)          (Middle)

C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/10/2015
(Street)

BLACKROCK, L2 00000
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares   2/10/2015     C    36   A   (1) 76   I   By Nexvet EBT Limited   (2)
Ordinary Shares   2/10/2015     C    56   A   (3) 132   I   By Nexvet EBT Limited   (2)
Ordinary Shares   2/10/2015     C    1696   A   (3) 7891   I   By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>   (4)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Investment Preference Shares     (1) 2/10/2015     C         36      (1)   (1) Ordinary Shares   36     (1) 0   I   By Nexvet EBT Limited   (2)
Series B Preference Shares     (3) 2/10/2015     C         56      (3)   (3) Ordinary Shares   56     (3) 0   I   By Nexvet EBT Limited   (2)
Series B Preference Shares     (3) 2/10/2015     C         1696      (3)   (3) Ordinary Shares   1696     (3) 0   I   By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C>   (4)

Explanation of Responses:
( 1)  Reflects automatic conversion of Series A Investment Preference Shares into ordinary shares on a one-for-one basis upon the completion of the initial public offering of Issuer's ordinary shares.
( 2)  The reporting person has voting and dispositive power over the reported securities pursuant to that certain Nominee Deed dated as of 11/14/14 by and between Nexvet EBT Limited and the persons named in the schedule thereto. Such Nominee Deed was executed in connection with Issuer's November 2014 four-for five share consolidation. The reporting person disclaims beneficial ownership of these reported securities except to the extent of her pecuniary interest therein.
( 3)  Reflects automatic conversion of Series B Preference Shares into ordinary shares on a one-for-one basis upon the completion of the initial public offering of Issuer's ordinary shares.
( 4)  The reporting person and her spouse share voting and dispositive power with respect to the reported securities.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Farrell Geraldine T
C/O NEXVET BIOPHARMA PLC
NATL INST, FOSTERS AVENUE, MOUNT MERRION
BLACKROCK, L2 00000

VP Operations & Genl Counsel

Signatures
/s/ Geraldine T. Farrell by Damian Lismore, Attorney-in-Fact 2/10/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more NEXVET BIOPHARMA PLC Charts.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more NEXVET BIOPHARMA PLC Charts.